Amazon (AMZN) partners with Exscientia to enhance drug discovery using AWS AI/ML services.

From Nasdaq: 2024-07-12 09:57:00

Amazon’s AMZN shares have surged 28.5% this year, exceeding industry growth. Key to this success is Amazon Web Services (AWS), which recently partnered with Exscientia to enhance drug discovery using AWS’s AI and ML services. AWS’s expanding customer base drove revenues of $25.04 billion in Q1 2024.

AWS’s customer momentum continues to grow, with companies like Smartsheet, F1, FWD Group, and SAP utilizing AWS’s generative AI solutions. Collaborations with NinjaTech AI, CrowdStrike, Brightcove, and Zilch further bolster AWS’s position in the cloud market.

AWS’s expanding portfolio and clientele position it strongly against competitors like Microsoft’s Azure and Alphabet’s Google Cloud. The Zacks #2 (Buy) company is expected to benefit from its focus on generative AI and cloud capabilities, contributing to Amazon’s overall financial growth.

As AWS’s client base and generative AI capabilities expand, Amazon’s future looks bright. Alongside e-commerce strengths in groceries and ultrafast delivery, AWS’s success in the cloud market, coupled with services like Prime Video, bode well for Amazon’s financial performance and market standing.



Read more at Nasdaq: Amazon (AMZN) Expands AWS Clientele With Exscientia Deal